Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer
NCT: NCT07767500 · NOT_YET_RECRUITING
Brief Summary
The purpose of this study is to investigate the use of an MR-guided linear accelerator to treat early stage renal cancer patients, considered inoperable or in patients declining surgerys. The study will collect efficacy, toxicity, and dosimetry data and assess the degree of improvement provided by this treatment technique. The primary objective is to evaluate whether magnetic resonance imaging (MRI)-guided radiation therapy (MRgRT) for primary renal cancer has an improved toxicity profile relative to conventional computed tomography (CT) based radiation therapy, as measured by the frequency of grade 2+ adverse events following MRgRT as per Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.
Frequently Asked Questions
What is Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer?
Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer is a clinical trial registered under NCT07767500. Current status: NOT_YET_RECRUITING.
What is the status of NCT07767500?
The current status of NCT07767500 (Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer) is: NOT_YET_RECRUITING.
When did Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer start?
Stereotactic MR-Adaptive Radiation Therapy for Early-stage Renal Cancer started on 2026-09.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.